{
  "metadata": {
    "timestamp": "2025-11-26T14:17:22.728981",
    "genes": [
      "AQP1",
      "ANOS1",
      "LIX1",
      "CD38",
      "RASL12",
      "KCNN3",
      "SERPINA3",
      "GFAP",
      "FAM189A2",
      "BBOX1",
      "NPSR1",
      "ITPKB",
      "CFI",
      "LINC01094",
      "ID3",
      "FBLN5",
      "CFAP54",
      "DAAM2",
      "ADAMTS8",
      "GGT5",
      "SLC14A1",
      "RPE65",
      "MASP1",
      "SLCO1C1",
      "AC092131.1",
      "ITGB4",
      "LRRC2",
      "STUM",
      "SPON1",
      "CD44",
      "ATP1A2",
      "AQP4",
      "ALDH1L1",
      "CRB2",
      "FAM107A",
      "GJA1",
      "ETNPPL",
      "AC103923.1",
      "ZFP36",
      "RFTN1",
      "EDNRA",
      "HAS2",
      "ADAMTS15",
      "MARVELD3",
      "OBI1-AS1",
      "PAPLN",
      "ID4",
      "HRH1",
      "HCG22",
      "DRC1",
      "PTCHD1",
      "PTPRT",
      "GALNT15",
      "FHAD1",
      "SLC44A3",
      "F3",
      "COL28A1",
      "EDNRB",
      "ACSBG1",
      "ABCA13",
      "WDR49",
      "XAF1",
      "ABCC3",
      "AC092924.2",
      "AC002429.2",
      "WWC1",
      "TIMP3",
      "AGT",
      "SLC24A4",
      "HOPX",
      "CABCOCO1",
      "CHI3L2",
      "C3",
      "MYBPC1",
      "ADGRV1",
      "LINC02234",
      "GPR37L1",
      "AL591686.2",
      "TCTEX1D1",
      "TTYH1",
      "TC2N",
      "LINC00844",
      "AL355306.2",
      "AC073941.1",
      "NMB",
      "PDGFRB",
      "BCAN",
      "EGF",
      "DCHS2",
      "PFKFB3",
      "AC117464.1",
      "SCN7A",
      "COLEC12",
      "OSMR",
      "C21orf62",
      "LTF",
      "BMPR1B",
      "ATP13A4",
      "IGFBP7"
    ],
    "context": "malignant glioblastoma cells",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "cached": false,
    "project": "glioblastoma_ds_auto",
    "query": "4_AC_gliosis_like_1",
    "source": "reorganization_script",
    "provider_config": {
      "timeout": 600,
      "max_retries": 3,
      "parameters": {
        "allowed_domains": [],
        "reasoning_effort": "medium",
        "search_domain_filter": [],
        "return_citations": true,
        "temperature": 0.0
      }
    },
    "citation_count": 60
  },
  "raw_response": {
    "markdown": "## Question\n\nPerform comprehensive literature analysis for the following gene list in the specified biological context.\n\n**Gene List**: [\"AQP1\", \"ANOS1\", \"LIX1\", \"CD38\", \"RASL12\", \"KCNN3\", \"SERPINA3\", \"GFAP\", \"FAM189A2\", \"BBOX1\", \"NPSR1\", \"ITPKB\", \"CFI\", \"LINC01094\", \"ID3\", \"FBLN5\", \"CFAP54\", \"DAAM2\", \"ADAMTS8\", \"GGT5\", \"SLC14A1\", \"RPE65\", \"MASP1\", \"SLCO1C1\", \"AC092131.1\", \"ITGB4\", \"LRRC2\", \"STUM\", \"SPON1\", \"CD44\", \"ATP1A2\", \"AQP4\", \"ALDH1L1\", \"CRB2\", \"FAM107A\", \"GJA1\", \"ETNPPL\", \"AC103923.1\", \"ZFP36\", \"RFTN1\", \"EDNRA\", \"HAS2\", \"ADAMTS15\", \"MARVELD3\", \"OBI1-AS1\", \"PAPLN\", \"ID4\", \"HRH1\", \"HCG22\", \"DRC1\", \"PTCHD1\", \"PTPRT\", \"GALNT15\", \"FHAD1\", \"SLC44A3\", \"F3\", \"COL28A1\", \"EDNRB\", \"ACSBG1\", \"ABCA13\", \"WDR49\", \"XAF1\", \"ABCC3\", \"AC092924.2\", \"AC002429.2\", \"WWC1\", \"TIMP3\", \"AGT\", \"SLC24A4\", \"HOPX\", \"CABCOCO1\", \"CHI3L2\", \"C3\", \"MYBPC1\", \"ADGRV1\", \"LINC02234\", \"GPR37L1\", \"AL591686.2\", \"TCTEX1D1\", \"TTYH1\", \"TC2N\", \"LINC00844\", \"AL355306.2\", \"AC073941.1\", \"NMB\", \"PDGFRB\", \"BCAN\", \"EGF\", \"DCHS2\", \"PFKFB3\", \"AC117464.1\", \"SCN7A\", \"COLEC12\", \"OSMR\", \"C21orf62\", \"LTF\", \"BMPR1B\", \"ATP13A4\", \"IGFBP7\"]\n\n**Biological Context**: malignant glioblastoma cells\n\n**Analysis Strategy**:\n1. Search current scientific literature for functional roles of each gene in the input list\n2. Identify clusters of genes that act together in pathways, processes, or cellular states\n3. Treat each cluster as a potential gene program within the list\n4. Interpret findings in light of both normal physiological roles and disease-specific alterations\n5. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant.\n\n**Guidelines**:\n* Anchor all predictions in either the normal physiology and development of the cell type and tissue specified in the context OR the alterations and dysregulations characteristic of the specified disease\n* Connect gene-level roles to program-level implications\n* Consider gene interactions, regulatory networks, and pathway dynamics\n* Highlight cases where multiple genes collectively strengthen evidence\n* Ensure all claims are backed by experimental evidence with proper attribution\n\n**Output**: Respond with JSON conforming to the provided schema - no prose, no markdown.  If you are unable to respond with JSON alone, make sure the text includes tables or fragments of schema compliant that unambiguously capture the elements and their associations that would be captured if returning JSON schema.\n\n```json\n{\n    \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n    \"title\": \"Gene Program Functional Analysis\",\n    \"description\": \"Comprehensive literature-based functional analysis of gene lists in specific biological contexts. Perform systematic analysis to identify gene programs - clusters of genes acting together in pathways, processes, or cellular states. For each program, predict functional implications for the specified cell type in the context of the provided disease and tissue environment. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant. Rank predictions higher when multiple genes from input list act in same process and when most/all required pathway components are present.\",\n    \"type\": \"object\",\n    \"required\": [\n        \"context\",\n        \"input_genes\",\n        \"programs\",\n        \"version\"\n    ],\n    \"definitions\": {\n        \"atomic_term\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"name\",\n                \"citation\",\n                \"genes\"\n            ],\n            \"properties\": {\n                \"name\": {\n                    \"type\": \"string\",\n                    \"description\": \"A minimal component of the gene program, representing a single biological process or cell component.\"\n                },\n                \"citations\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"$ref\": \"#/definitions/citation\"\n                    },\n                    \"description\": \"list of citations supporting the role of the listed genes in the name biological process or cell component\"\n                },\n                \"genes\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"Genes of the program whose products are involved in this biological process or cell component.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"citation\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"source_id\"\n            ],\n            \"properties\": {\n                \"source_id\": {\n                    \"type\": \"string\"\n                },\n                \"notes\": {\n                    \"type\": \"string\",\n                    \"description\": \"Why this citation supports the claim.\"\n                }\n            },\n            \"additionalProperties\": false\n        }\n    },\n    \"properties\": {\n        \"context\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"cell_type\",\n                \"disease\"\n            ],\n            \"properties\": {\n                \"cell_type\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the name or names of the primary cell type(s) from the provided biological context. Use standard cell type terminology. Leave blank if not specified.\"\n                },\n                \"disease\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the disease or pathological condition from the provided biological context (e.g., 'IDH-mutant astrocytoma', 'Alzheimer disease', 'multiple sclerosis'). Use standard disease terminology. Leave blank if not specified.\"\n                },\n                \"tissue\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the tissue or anatomical location if mentioned in the biological context (e.g., 'brain', 'cerebral cortex', 'hippocampus'). Leave blank if not specified.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"input_genes\": {\n            \"type\": \"array\",\n            \"items\": {\n                \"type\": \"string\",\n                \"minLength\": 1\n            },\n            \"minItems\": 1,\n            \"uniqueItems\": true\n        },\n        \"programs\": {\n            \"type\": \"array\",\n            \"minItems\": 1,\n            \"items\": {\n                \"type\": \"object\",\n                \"required\": [\n                    \"program_name\",\n                    \"description\",\n                    \"predicted_cellular_impact\",\n                    \"evidence_summary\",\n                    \"significance_score\",\n                    \"citations\",\n                    \"supporting_genes\"\n                ],\n                \"description\": \"A gene program, relevant to the provided context. Avoid programs that group 2 or more loosely related processes\",\n                \"properties\": {\n                    \"program_name\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"Provide a concise, descriptive name for this gene program that captures its primary biological function or pathway. Use 2-5 words maximum.\"\n                    },\n                    \"description\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"A more detailed description of the gene program.\"\n                    },\n                    \"atomic_biological_processes\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic biological process terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"atomic_cellular_components\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic cellular component terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"predicted_cellular_impact\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\",\n                            \"description\": \"Concise bullet-level impacts (e.g., ‘enhanced focal adhesion signaling’)\"\n                        }\n                    },\n                    \"evidence_summary\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1\n                    },\n                    \"significance_score\": {\n                        \"description\": \"A value between 0 and 1 that ranks this gene program by the number of supporting genes, the number of supporting references and relevance to the context.\",\n                        \"type\": \"number\",\n                        \"minimum\": 0.0,\n                        \"maximum\": 1.0\n                    },\n                    \"citations\": {\n                        \"description\": \"Array of citations supporting the role of the listed genes in this gene program.\",\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"$ref\": \"#/definitions/citation\"\n                        }\n                    },\n                    \"supporting_genes\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\"\n                        },\n                        \"uniqueItems\": true\n                    },\n                    \"required_genes_not_in_input\": {\n                        \"description\": \"Genes required for this program that are NOT present in the input genes.\",\n                        \"type\": \"object\",\n                        \"properties\": {\n                            \"genes\": {\n                                \"type\": \"array\",\n                                \"items\": {\n                                    \"type\": \"string\"\n                                }\n                            },\n                            \"citations\": {\n                                \"type\": \"array\",\n                                \"minItems\": 1,\n                                \"items\": {\n                                    \"$ref\": \"#/definitions/citation\"\n                                }\n                            }\n                        }\n                    }\n                },\n                \"additionalProperties\": false\n            }\n        },\n        \"method\": {\n            \"type\": \"object\",\n            \"description\": \"Optional trace of how programs were derived\",\n            \"properties\": {\n                \"clustering_basis\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"e.g., pathway databases, co-citation, PPI, co-expression\"\n                },\n                \"notes\": {\n                    \"type\": \"string\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"version\": {\n            \"type\": \"string\"\n        }\n    },\n    \"additionalProperties\": false\n}\n\n```\n\n## Output\n\n<think>\nThis is a complex request asking me to analyze a comprehensive gene list in the context of malignant glioblastoma cells. The user wants me to:\n\n1. Identify functional roles of each gene from the search results\n2. Find clusters of genes working together in pathways/processes\n3. Treat each cluster as a potential gene program\n4. Ground predictions in normal physiology OR disease-specific alterations\n5. Output as JSON following a specific schema\n\nLet me examine the search results to understand what's available about these genes in the glioblastoma context.\n\nFrom the search results, I can extract information about:\n- AQP1 and AQP4: water channels involved in glioma edema, migration, glycolysis regulation\n- CD38: multifunctional ectoenzyme, involved in complement system, NAD+ metabolism\n- CD44: expressed in glioma, involved in migration, stemness via osteopontin signaling\n- GFAP: astrocyte marker, reactive astrocytes in tumor microenvironment\n- ALDH1L1: astrocyte/glial progenitor marker\n- GJA1 (Connexin 43): gap junction protein, involved in chemoresistance\n- HAS2 and HAS3: hyaluronic acid synthesis, promotes invasion and migration\n- ITGB4: integrin involved in migration and invasion\n- TIMP3: tissue inhibitor of metalloproteinases\n- ADAMTS8: inhibits glioma development\n- EDNRA/EDNRB: endothelin signaling for GSC maintenance\n- PFKFB3: glycolytic enzyme\n- GLUT1/GLUT3: glucose transporters\n- CHI3L2 (YKL40): immune infiltration, poor prognosis\n- C3: complement component, associated with aggressive disease\n- IGFBP7: promotes migration and growth\n- ZFP36L2: immune infiltration, prognosis biomarker\n\n\n- BCAN: brevican, proteoglycan in extracellular matrix supporting tumor cell interactions\n- PDGFRB: critical pericyte marker indicating tumor vasculature development\n- NMB: neuromedin B potentially linked to tumor cell survival mechanisms\n- COLEC12: immune modulation protein potentially influencing tumor microenvironment\n- EGF: growth factor stimulating cellular proliferation and migration\n- HOPX: radial progenitor marker suggesting neural stem cell characteristics\n\nI'll focus on identifying potential functional clusters and interactions that might reveal underlying tumor progression mechanisms.\n\nThe intermediate-conductance K+ channel (KCNN3) appears integral to cellular migration dynamics, complementing the ion transport and volume regulation network involving AQP1, AQP4, and ATP1A2.\n\nThese molecular markers suggest complex interactions between cellular migration, metabolic reprogramming, and microenvironmental adaptation in glioma progression.\n\nKey pathways involve ion gradient maintenance, intercellular communication mechanisms, and adaptive cellular responses that enable tumor cell motility and survival.\n\nThe systematic organization reveals interconnected molecular programs driving tumor cell plasticity, with ion channels serving critical roles in migration and chemoresistance strategies.\n</think>\n\n```json\n{\n  \"context\": {\n    \"cell_type\": \"Glioblastoma multiforme cells; tumor-associated astrocytes; infiltrating immune cells\",\n    \"disease\": \"Glioblastoma multiforme (GBM); malignant glioma\",\n    \"tissue\": \"Central nervous system; brain\"\n  },\n  \"input_genes\": [\n    \"AQP1\",\n    \"ANOS1\",\n    \"LIX1\",\n    \"CD38\",\n    \"RASL12\",\n    \"KCNN3\",\n    \"SERPINA3\",\n    \"GFAP\",\n    \"FAM189A2\",\n    \"BBOX1\",\n    \"NPSR1\",\n    \"ITPKB\",\n    \"CFI\",\n    \"LINC01094\",\n    \"ID3\",\n    \"FBLN5\",\n    \"CFAP54\",\n    \"DAAM2\",\n    \"ADAMTS8\",\n    \"GGT5\",\n    \"SLC14A1\",\n    \"RPE65\",\n    \"MASP1\",\n    \"SLCO1C1\",\n    \"AC092131.1\",\n    \"ITGB4\",\n    \"LRRC2\",\n    \"STUM\",\n    \"SPON1\",\n    \"CD44\",\n    \"ATP1A2\",\n    \"AQP4\",\n    \"ALDH1L1\",\n    \"CRB2\",\n    \"FAM107A\",\n    \"GJA1\",\n    \"ETNPPL\",\n    \"AC103923.1\",\n    \"ZFP36\",\n    \"RFTN1\",\n    \"EDNRA\",\n    \"HAS2\",\n    \"ADAMTS15\",\n    \"MARVELD3\",\n    \"OBI1-AS1\",\n    \"PAPLN\",\n    \"ID4\",\n    \"HRH1\",\n    \"HCG22\",\n    \"DRC1\",\n    \"PTCHD1\",\n    \"PTPRT\",\n    \"GALNT15\",\n    \"FHAD1\",\n    \"SLC44A3\",\n    \"F3\",\n    \"COL28A1\",\n    \"EDNRB\",\n    \"ACSBG1\",\n    \"ABCA13\",\n    \"WDR49\",\n    \"XAF1\",\n    \"ABCC3\",\n    \"AC092924.2\",\n    \"AC002429.2\",\n    \"WWC1\",\n    \"TIMP3\",\n    \"AGT\",\n    \"SLC24A4\",\n    \"HOPX\",\n    \"CABCOCO1\",\n    \"CHI3L2\",\n    \"C3\",\n    \"MYBPC1\",\n    \"ADGRV1\",\n    \"LINC02234\",\n    \"GPR37L1\",\n    \"AL591686.2\",\n    \"TCTEX1D1\",\n    \"TTYH1\",\n    \"TC2N\",\n    \"LINC00844\",\n    \"AL355306.2\",\n    \"AC073941.1\",\n    \"NMB\",\n    \"PDGFRB\",\n    \"BCAN\",\n    \"EGF\",\n    \"DCHS2\",\n    \"PFKFB3\",\n    \"AC117464.1\",\n    \"SCN7A\",\n    \"COLEC12\",\n    \"OSMR\",\n    \"C21orf62\",\n    \"LTF\",\n    \"BMPR1B\",\n    \"ATP13A4\",\n    \"IGFBP7\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Aquaporin-mediated osmotic water transport and migration\",\n      \"description\": \"Water channel proteins (AQP1, AQP4) regulate osmotic gradients essential for glioma cell migration and edema formation. AQP4 localizes to leading edges of migrating cells and lamellipodia, facilitating volume changes during invasion through narrow extracellular spaces. Coordinated with ion transporters (KCNN3, ATP1A2, SLC14A1) that maintain ion gradients driving osmotic water flux. Dysregulation contributes to both tumor-associated vasogenic edema and enhanced invasive capability.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"osmotic water transport and cell volume regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"AQP4 redistribution and upregulation in glioma cells; high water flux capacity; association with KCl-water extrusion enhancing cell invasion\"\n            },\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"AQP1 induction by glycolysis; role in tumor edema and cell migration through osmotic gradient mechanisms\"\n            }\n          ],\n          \"genes\": [\n            \"AQP1\",\n            \"AQP4\"\n          ]\n        },\n        {\n          \"name\": \"ion channel activity and electrical signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"KCNN3 (KCa3.1) channels modulate glioma cell infiltration; involved in CXCL12-induced migration\"\n            },\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"ATP1A2 (Na+/K+-ATPase) consumes 20% of astrocytic ATP; maintains ion gradients essential for cell migration\"\n            },\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"SLC14A1 (UT-B) expressed in astrocytes; facilitates urea and water transport\"\n            }\n          ],\n          \"genes\": [\n            \"KCNN3\",\n            \"ATP1A2\",\n            \"SLC14A1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"plasma membrane water and solute transporters\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"AQP4 expression at leading edge of migratory glioma cells; co-localization with CLC2 and KCC1 ion channels\"\n            }\n          ],\n          \"genes\": [\n            \"AQP1\",\n            \"AQP4\",\n            \"KCNN3\",\n            \"ATP1A2\",\n            \"SLC14A1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced directional cell migration through osmotic volume regulation\",\n        \"Increased infiltration of tumor cells through brain parenchyma\",\n        \"Promotion of vasogenic edema formation at tumor-brain interface\",\n        \"Support for invasive cell membrane protrusions (lamellipodia formation)\",\n        \"Maintenance of perivascular migration along blood vessel corridors\"\n      ],\n      \"evidence_summary\": \"Multiple lines of evidence demonstrate that aquaporin-mediated water transport is upregulated in gliomas and essential for invasive phenotype. AQP4 shows strong redistribution at tumor cell leading edges, co-localizing with ion channels (KCC1, CLC2) to facilitate coordinated water and ion extrusion that enables cell volume changes required for invasion through narrow extracellular spaces. The coupling of water channels with intermediate-conductance K+ channels (KCNN3) and Na+/K+-ATPase creates osmotic gradients driving migration. This program is specifically dysregulated in glioma compared to normal brain tissue.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Comprehensive review of AQP4 roles in glioma migration, invasive phenotype, and cell volume changes\"\n        },\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"AQP1 upregulation by glycolysis; localization in perivascular regions supporting invasive phenotype\"\n        },\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"KCNN3 inhibition reduces glioma infiltration and astrogliosis in vivo\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"AQP1\",\n        \"AQP4\",\n        \"KCNN3\",\n        \"ATP1A2\",\n        \"SLC14A1\"\n      ]\n    },\n    {\n      \"program_name\": \"Aerobic glycolysis-dependent nutrient acquisition\",\n      \"description\": \"Glioblastomas exhibit constitutive aerobic glycolysis despite adequate oxygen (Warburg effect), characterized by upregulation of glycolytic enzymes and glucose transporters. PFKFB3 is the most highly expressed glycolytic regulator in GBM, controlling the rate-limiting step through F-2,6-BP production. This metabolic state is driven by hypoxic microenvironments and genetic alterations (EGFR amplification, PTEN loss). Elevated glycolysis supports both energy production and anabolic biosynthesis, driving tumor cell proliferation and survival. This program is inseparable from invasion, as perivascular glioma cells show peak glycolytic enzyme expression including AQP1, LDH, and cathepsin B.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"glucose uptake and phosphorylation\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"GLUT1 and GLUT3 upregulation in GBM; silencing reduces glioma stem cell tumor sphere formation\"\n            }\n          ],\n          \"genes\": [\n            \"PFKFB3\"\n          ]\n        },\n        {\n          \"name\": \"glycolytic pathway flux regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"PFKFB3 O-GlcNAcylation essential for cancer cell division under hypoxia; controls PFKFB3-G3BP2-P27 signaling\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"PFKFB3 inhibition decreases glycolysis rate and tumor cell proliferation; combination with VEGF inhibitors prolongs survival\"\n            }\n          ],\n          \"genes\": [\n            \"PFKFB3\"\n          ]\n        },\n        {\n          \"name\": \"lactate production and extracellular acidification\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"AQP1 induction correlates with LDH expression in perivascular glioma regions; supports acidification of extracellular milieu\"\n            }\n          ],\n          \"genes\": [\n            \"AQP1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"glycolytic enzyme complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"PFKFB3 is rate-limiting enzyme in glycolysis; most highly expressed in GBM\"\n            }\n          ],\n          \"genes\": [\n            \"PFKFB3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced ATP production supporting tumor growth and proliferation\",\n        \"Increased lactate and H+ secretion promoting acidic tumor microenvironment\",\n        \"Support for anabolic pathways (nucleotide, lipid, amino acid synthesis)\",\n        \"Hypoxia adaptation and maintenance of hypoxic metabolic state\",\n        \"Coupling with angiogenic escape mechanisms to overcome anti-VEGF therapy\"\n      ],\n      \"evidence_summary\": \"PFKFB3 emerges as a central node controlling glycolytic flux in GBM. Its expression is induced by hypoxia through multiple mechanisms including O-GlcNAcylation and ERK phosphorylation. PFKFB3 inhibitors (3-PO, PFK15, KAN0438757) significantly reduce GBM cell viability and migration in preclinical models. Combination strategies targeting PFKFB3 with VEGF inhibitors (bevacizumab) show synergistic effects in extending survival and improving drug delivery. The program is further supported by upregulation of AQP1 in perivascular regions showing peak glycolytic enzyme expression, suggesting metabolic zonation within tumors.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"37\",\n          \"notes\": \"Hypoxia-induced PFKFB3 O-GlcNAcylation maintains cancer cell division\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"Comprehensive review of PFKFB3-targeted therapy approaches in GBM\"\n        },\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"AQP1 induction by glycolysis and perivascular metabolic zonation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PFKFB3\",\n        \"AQP1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"GLUT1\",\n          \"GLUT3\",\n          \"LDH\",\n          \"HIF1A\",\n          \"LDHA\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"40\",\n            \"notes\": \"GLUT1/GLUT3 glucose transporters essential for nutrient uptake; upregulated in GBM\"\n          },\n          {\n            \"source_id\": \"4\",\n            \"notes\": \"LDH (lactate dehydrogenase) co-induced with AQP1 in perivascular glioma regions\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular matrix remodeling and invasive phenotype\",\n      \"description\": \"Glioma cells exhibit dynamic ECM remodeling through coordinated synthesis (HAS2, HAS3 driving hyaluronic acid accumulation) and degradation (ADAMTS8, TIMP3, matrix metalloproteinases). CD44 serves as the primary HA receptor, engaging osteopontin (OPN/SPP1) signaling to promote migration, invasion, and stemness. IGFBP7 promotes glioma cell migration through AKT-ERK pathway activation. Increased ECM deposition (particularly brevican/BCAN and other proteoglycans) creates a denser, more resistant tumor microenvironment. HAS2 expression correlates with poor prognosis and GBM subtype (IDH-WT, non-1p/19q codeletion). Loss of ADAMTS8 (an inhibitory protease) contributes to glioma progression.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"hyaluronic acid synthesis and accumulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"HAS2 elevated in GBM; promotes proliferation, migration, invasion; associated with poor survival\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"HAS3 upregulated in GBM; silencing inhibits proliferation, migration, invasion; blocks autophagy flux\"\n            }\n          ],\n          \"genes\": [\n            \"HAS2\"\n          ]\n        },\n        {\n          \"name\": \"CD44-mediated ECM receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"CD44 expression elevated in GBM; astrocytes upregulate glioma CD44; CD44+ cells interact with M1 macrophages via osteopontin\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"CD44 antibody blocking inhibits glioma cell proliferation; blocks autophagy and cell cycle\"\n            }\n          ],\n          \"genes\": [\n            \"CD44\"\n          ]\n        },\n        {\n          \"name\": \"matrix metalloproteinase regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"Id4 suppresses MMP2-mediated invasion by direct inhibition of Twist1; Id4 expression correlates with GBM patient survival\"\n            },\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"TIMP3 locally balances MMP activity; expression associated with prognosis\"\n            }\n          ],\n          \"genes\": [\n            \"TIMP3\",\n            \"ADAMTS8\",\n            \"ID4\"\n          ]\n        },\n        {\n          \"name\": \"integrin-mediated cell adhesion and migration\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"ITGB4 promotes tumor migration and invasion through FAK-PI3K/AKT and MAPK pathways; released from hemidesmosomes in cancer\"\n            },\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"ITGB4 upregulated in GBM; predicts poor prognosis; interacts with tumor-associated fibroblasts\"\n            }\n          ],\n          \"genes\": [\n            \"ITGB4\"\n          ]\n        },\n        {\n          \"name\": \"IGF binding protein signaling in migration\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"IGFBP7 expression correlates with glioma grade; promotes migration through AKT-ERK pathway; associated with laminin-stained GBM vessels\"\n            }\n          ],\n          \"genes\": [\n            \"IGFBP7\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"extracellular matrix proteoglycans and glycosaminoglycans\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"Brevican (BCAN) most abundantly detected proteoglycan in adult and pediatric gliomas\"\n            },\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"Hyaluronic acid (HA) vital component of ECM; upregulated in GBM; stimulates migration and invasion\"\n            }\n          ],\n          \"genes\": [\n            \"BCAN\",\n            \"HAS2\",\n            \"FBLN5\",\n            \"PAPLN\"\n          ]\n        },\n        {\n          \"name\": \"adhesion molecules and integrin receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"ITGB4 (integrin β4) functions as mechanosensor; mediates bidirectional exchange between intracellular and extracellular matrices\"\n            }\n          ],\n          \"genes\": [\n            \"ITGB4\",\n            \"CD44\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced tumor cell migration and invasion through remodeled ECM\",\n        \"Increased stemness and self-renewal via CD44-osteopontin signaling\",\n        \"Promotion of epithelial-mesenchymal transition (EMT)\",\n        \"Increased resistance to anti-angiogenic therapy through altered ECM composition\",\n        \"Support for perivascular migration and vascular co-option\",\n        \"Enhanced mechanotransduction signaling through integrin-FAK pathways\"\n      ],\n      \"evidence_summary\": \"ECM remodeling represents a core pathological feature of GBM progression. HAS2 upregulation drives excessive hyaluronic acid (HA) accumulation, which promotes migration and invasion through CD44 receptors. CD44+ glioma cells display enhanced interaction with macrophages via osteopontin signaling, creating bidirectional cross-talk between tumor and immune cells. ITGB4 (integrin β4) is specifically upregulated in GBM and predicts poor prognosis, promoting migration through FAK-PI3K/AKT and MAPK activation. IGFBP7 expression correlates with tumor grade and localizes to perivascular regions, supporting invasion along blood vessels. The balance between matrix synthesis and degradation is controlled by ADAMTS proteases and TIMPs; loss of ADAMTS8 (an inhibitory protease) contributes to disease progression.\",\n      \"significance_score\": 0.89,\n      \"citations\": [\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"HAS2 promotes glioma malignancy and suppresses ferroptosis\"\n        },\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"CD44 as prognostic factor in glioma; interaction with stromal cells in TME\"\n        },\n        {\n          \"source_id\": \"12\",\n          \"notes\": \"ITGB4 upregulation in lower-grade glioma; association with immune infiltration\"\n        },\n        {\n          \"source_id\": \"39\",\n          \"notes\": \"IGFBP7 mediates glioma cell migration through AKT-ERK pathway\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"HAS2\",\n        \"CD44\",\n        \"ITGB4\",\n        \"IGFBP7\",\n        \"TIMP3\",\n        \"ADAMTS8\",\n        \"ID4\",\n        \"BCAN\",\n        \"FBLN5\"\n      ]\n    },\n    {\n      \"program_name\": \"Complement system activation and immune modulation\",\n      \"description\": \"The complement cascade is activated within gliomas through multiple pathways (classical via C1q, alternative, and lectin pathways via MASP1/MASP2/COLEC12). Complement components C3 and C5 generate potent anaphylatoxins (C3a, C5a) that promote M2 macrophage polarization and immunosuppression. C3a-C3aR signaling in glioma stem cells (GSCs) maintains stemness through STAT-3 and Wnt/SOX2 pathways. CD38 functions as an ectoenzyme converting NAD+ to immunosuppressive adenosine and ADPR. CHI3L2 (YKL40) is secreted by tumor and immune cells, promoting inflammatory responses and inducing CD8+ T cell apoptosis. This program collectively shifts the immune microenvironment toward M2/immunosuppressive phenotypes.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"complement classical pathway activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"C1q highly expressed in gliomas; promotes tumor proliferation and invasion; negatively correlates with survival\"\n            },\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"Glioma cells express complement regulators (CD46, CD55, CD59); resist complement-mediated lysis\"\n            }\n          ],\n          \"genes\": [\n            \"C3\",\n            \"MASP1\"\n          ]\n        },\n        {\n          \"name\": \"complement lectin pathway activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"MBL-MASP pathway components (MBL, MASP1, MASP3) highly expressed in glioma cell lines\"\n            },\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"COLEC12 functions as pattern-recognition molecule; activates complement alternative pathway\"\n            }\n          ],\n          \"genes\": [\n            \"MASP1\",\n            \"COLEC12\",\n            \"CFI\"\n          ]\n        },\n        {\n          \"name\": \"C3a-C3aR signaling in glioma stem cells\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"C3a-C3aR interaction activates STAT-3; increases Wnt2b and SOX2 expression; maintains GSC phenotype\"\n            },\n            {\n              \"source_id\": \"34\",\n              \"notes\": \"Hypoxia-induced C3 expression; C3a promotes M2 macrophage polarization; C3aR antagonism prolongs survival\"\n            }\n          ],\n          \"genes\": [\n            \"C3\"\n          ]\n        },\n        {\n          \"name\": \"CD38-mediated immunosuppression through adenosine production\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"CD38 deficiency attenuates glioma progression; associated with increased cell death and decreased MMP expression\"\n            },\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"CD38 inhibition important in pre-recurrent GBM; conventional therapies increase CD38 activity in recurrent tumors\"\n            }\n          ],\n          \"genes\": [\n            \"CD38\"\n          ]\n        },\n        {\n          \"name\": \"chitinase-like protein immune modulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"CHI3L2 induces apoptosis of CD8+ T cells; high expression associated with poor prognosis in glioma\"\n            },\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"CHI3L1 (YKL40) promotes activation of macrophages; upregulates pro-inflammatory cytokines; increases tumor-infiltrating immune cells\"\n            }\n          ],\n          \"genes\": [\n            \"CHI3L2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"complement cascade proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"C1q, C3, C5 components; convertases C3b, C5b\"\n            }\n          ],\n          \"genes\": [\n            \"C3\",\n            \"MASP1\",\n            \"COLEC12\",\n            \"CFI\"\n          ]\n        },\n        {\n          \"name\": \"complement receptor and anaphylatoxin receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"C3aR and C5aR (CD88) mediate G-protein coupled receptor signaling\"\n            }\n          ],\n          \"genes\": [\n            \"C3\"\n          ]\n        },\n        {\n          \"name\": \"ectoenzymes and surface receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"CD38 ectoenzyme uses NAD+ as substrate; generates ADPR and cADPR\"\n            }\n          ],\n          \"genes\": [\n            \"CD38\",\n            \"CHI3L2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Polarization of infiltrating macrophages/microglia toward M2 (immunosuppressive) phenotype\",\n        \"Maintenance of glioma stem cell phenotype through C3a-STAT3-SOX2 signaling\",\n        \"Suppression of CD8+ T cell function and promotion of regulatory T cell (Treg) differentiation\",\n        \"Promotion of tumor angiogenesis through complement-endothelial cell interactions\",\n        \"Enhanced resistance to complement-mediated lysis via CD46/CD55/CD59 upregulation\",\n        \"Conversion of adaptive immune responses from Th1 to Th2/immunosuppressive phenotype\"\n      ],\n      \"evidence_summary\": \"Complement activation represents a critical mechanism of immune evasion in GBM. C3 expression increases with glioma grade, is associated with worse survival, and preferentially localizes to hypoxic tumor regions. C3a/C3aR signaling maintains GSC stemness through STAT-3 and Wnt/SOX2 pathways, while simultaneously promoting M2 macrophage polarization. CD38 functions as an ectoenzyme converting NAD+ to immunosuppressive metabolites; CD38 inhibition with FDA-approved therapeutics extends survival in preclinical models. CHI3L2 (YKL40) is secreted by both tumor and immune cells, directly inducing CD8+ T cell apoptosis. The complement lectin pathway (MASP1, COLEC12) is upregulated in gliomas and provides an alternative route to C3 activation. Gliomas upregulate complement regulators (CD46, CD55, CD59) to resist complement-mediated lysis.\",\n      \"significance_score\": 0.87,\n      \"citations\": [\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"Complement system in glioblastoma multiforme; C3a maintains GSC phenotype\"\n        },\n        {\n          \"source_id\": \"34\",\n          \"notes\": \"Hypoxia-induced complement C3 promotes M2 macrophage polarization; C3aR antagonism extends survival\"\n        },\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"CD38 deficiency attenuates glioma progression\"\n        },\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"CHI3L2 is prognostic biomarker in glioma; induces CD8+ T cell apoptosis\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"C3\",\n        \"CD38\",\n        \"CHI3L2\",\n        \"MASP1\",\n        \"COLEC12\",\n        \"CFI\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"C5\",\n          \"C1Q\",\n          \"CD46\",\n          \"CD55\",\n          \"CD59\",\n          \"C5AR1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"31\",\n            \"notes\": \"C1q initiates classical pathway; C5 generates C5a for immune cell recruitment\"\n          },\n          {\n            \"source_id\": \"32\",\n            \"notes\": \"CD46, CD55, CD59 complement membrane regulators highly expressed in gliomas\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Glioma stem cell self-renewal and maintenance\",\n      \"description\": \"Glioma stem cells (GSCs) reside in perivascular and hypoxic niches where they maintain multipotency and self-renewal capacity. Endothelin-3 (EDN3) and endothelin receptor B (EDNRB) autocrine signaling is essential for GSC maintenance; blocking EDNRB induces apoptosis and impairs tumor-sphere formation. HOPX marks radial progenitor-like cells in glioma. CD44 and osteopontin (OPN) signaling within the perivascular niche promotes stem cell phenotypes and tumor growth. Complement C3a signaling through C3aR maintains GSCs via STAT-3 and Wnt/SOX2 activation. IGFBP7 and growth factor signaling support GSC migration along blood vessels. ID3 and ID4 (inhibitors of differentiation) regulate GSC proliferation and maintain undifferentiated state.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"endothelin signaling for stemness maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"Autocrine EDN3/EDNRB signaling essential for GSC maintenance; blockade leads to apoptosis and loss of tumor-sphere formation\"\n            },\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"Hypoxia upregulates EDN1, EDNRA, EDNRB, and ECE1; hypoxia-ERN1 axis drives endothelin system expression\"\n            }\n          ],\n          \"genes\": [\n            \"EDNRA\",\n            \"EDNRB\"\n          ]\n        },\n        {\n          \"name\": \"CD44-osteopontin perivascular niche signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"OPN-CD44 signaling in glioma perivascular niche promotes cancer stem cell phenotypes; SPP1 (osteopontin) negatively correlates with survival\"\n            }\n          ],\n          \"genes\": [\n            \"CD44\"\n          ]\n        },\n        {\n          \"name\": \"complement-mediated GSC maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Autocrine C3a from GSCs activates C3aR; increases Wnt2b and SOX-2 expression; maintains stemness\"\n            },\n            {\n              \"source_id\": \"34\",\n              \"notes\": \"C3aR antagonism reduces glioma stem cell self-renewal capability\"\n            }\n          ],\n          \"genes\": [\n            \"C3\"\n          ]\n        },\n        {\n          \"name\": \"inhibitor of differentiation transcription factors\",\n          \"citations\": [\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"ID4 expression in glioblastoma; inhibitor of differentiation protein family involved in cell cycle control and tumorigenesis\"\n            }\n          ],\n          \"genes\": [\n            \"ID3\",\n            \"ID4\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"perivascular niche microenvironment\",\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"Endothelial-secreted Endocan activates PDGFRA; promotes proliferation and migration; GBM cells in perivascular niche maintain GSC phenotype\"\n            }\n          ],\n          \"genes\": [\n            \"CD44\",\n            \"EDNRA\",\n            \"EDNRB\",\n            \"HOPX\"\n          ]\n        },\n        {\n          \"name\": \"hypoxic microenvironment sensing\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"EDN3/EDNRB signaling expressed in response to hypoxia in GSCs\"\n            }\n          ],\n          \"genes\": [\n            \"EDNRA\",\n            \"EDNRB\",\n            \"C3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Maintenance of undifferentiated GSC phenotype and multipotency\",\n        \"Enhanced self-renewal capacity and tumor-sphere formation\",\n        \"Increased resistance to differentiation-inducing signals\",\n        \"Support for perivascular localization and niche interaction\",\n        \"Enhanced survival signaling through multiple pathways (EDN, complement, CD44)\",\n        \"Promotion of tumor recurrence through GSC persistence\"\n      ],\n      \"evidence_summary\": \"Glioma stem cell maintenance depends on coordinated signaling within specialized microenvironmental niches. Autocrine endothelin-3 (EDN3) signaling through EDNRB is both necessary and sufficient for GSC phenotype maintenance; blocking EDNRB induces apoptosis and loss of self-renewal capacity. CD44 expression in GSCs engages osteopontin (OPN) signaling to promote stemness within the perivascular niche. Complement component C3 generated by GSCs activates C3aR to drive STAT-3 and Wnt/SOX-2 pathways that reinforce stemness. HOPX marks a subset of radial progenitor-like GSCs. This program represents a critical mechanism of treatment resistance, as GSCs survive conventional therapies and drive recurrence.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"Autocrine endothelin-3/EDNRB signaling maintains glioma stem cells\"\n        },\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"CD44-osteopontin signaling promotes GSC phenotype in perivascular niche\"\n        },\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"Complement C3a maintains GSC phenotype through STAT-3 and Wnt signaling\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"EDNRA\",\n        \"EDNRB\",\n        \"CD44\",\n        \"C3\",\n        \"HOPX\",\n        \"ID3\",\n        \"ID4\",\n        \"IGFBP7\"\n      ]\n    },\n    {\n      \"program_name\": \"Tumor-associated astrocyte and glial cell reprogramming\",\n      \"description\": \"Peritumoral and tumor-resident astrocytes undergo reactive transformation (gliosis) characterized by GFAP upregulation. Tumor-associated astrocytes (TAAs) display distinct morphology and transcriptomic profiles depending on anatomical location (tumor core, periphery, perivascular niche, border). ALDH1L1 marks gliogenic precursors and mature astrocytes. TAAs enhance glioma cell viability and migration by upregulating CD44 expression in tumor cells through paracrine mechanisms. Reactive astrocytes modulate immune cell recruitment through purinergic signaling (ATP/adenosine metabolism, CD73). This program represents a critical stromal-tumor interaction that supports malignancy.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"reactive astrocyte transformation and GFAP upregulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"Tumor-associated astrocytes (TAAs) exhibit spatially organized gene expression; distinct phenotypes in tumor core, periphery, and perivascular niches\"\n            },\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"GFAP expression in white matter fibrous and reactive astrocytes; ALDH1L1 marks gliogenic precursors\"\n            }\n          ],\n          \"genes\": [\n            \"GFAP\",\n            \"ALDH1L1\"\n          ]\n        },\n        {\n          \"name\": \"TAA-mediated enhancement of glioma malignancy\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"Astrocytes enhance glioma CD44 expression; promote glioma cell migration and viability; coordinate with M1 macrophages via osteopontin signaling\"\n            }\n          ],\n          \"genes\": [\n            \"GFAP\",\n            \"CD44\"\n          ]\n        },\n        {\n          \"name\": \"purinergic signaling in astrocyte-immune cell cross-talk\",\n          \"citations\": [\n            {\n              \"source_id\": \"38\",\n              \"notes\": \"ATP released by astrocytes; adenosine (ADO) produced by CD73; A2A receptor activation promotes immunosuppressive A2-like astrocyte phenotype\"\n            }\n          ],\n          \"genes\": [\n            \"GFAP\",\n            \"ATP1A2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"intermediate filament networks\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"GFAP cytoskeletal protein; primary marker of astrocyte cell type\"\n            }\n          ],\n          \"genes\": [\n            \"GFAP\"\n          ]\n        },\n        {\n          \"name\": \"astrocyte metabolic enzymes\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"ALDH1L1 folate metabolic enzyme; bona fide astrocyte marker; broadly expressed in fibrous and protoplasmic astrocytes\"\n            }\n          ],\n          \"genes\": [\n            \"ALDH1L1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced glioma cell migration and viability through astrocyte-derived paracrine factors\",\n        \"Upregulation of stemness-promoting genes (CD44) in adjacent tumor cells\",\n        \"Promotion of M1 macrophage infiltration and immune cell recruitment\",\n        \"Increased extracellular adenosine production creating immunosuppressive microenvironment\",\n        \"Support for perivascular tumor cell positioning and angiogenic cooperation\",\n        \"Modulation of blood-brain barrier permeability\"\n      ],\n      \"evidence_summary\": \"Tumor-associated astrocytes (TAAs) play a critical supporting role in glioma progression through bidirectional cross-talk with tumor cells and immune cells. Spatial transcriptomics reveals distinct TAA phenotypes in tumor core (perivascular TAAs expressing CD44 and Tenascin-C) versus tumor periphery (morphologically resembling reactive astrocytes). Astrocytes enhance glioma CD44 expression, promoting migration and stemness through paracrine signaling. TAAs display heterogeneous transcriptomic profiles reflecting their adaptive responses to microenvironmental cues. Purinergic signaling through ATP and adenosine creates an immunosuppressive microenvironment. This program highlights the complex three-way interaction between tumor cells, stromal astrocytes, and immune cells.\",\n      \"significance_score\": 0.80,\n      \"citations\": [\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"Spatial transcriptomics reveals heterogeneous tumor-associated astrocyte phenotypes\"\n        },\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"Astrocytes enhance glioma CD44 expression and promote malignancy\"\n        },\n        {\n          \"source_id\": \"38\",\n          \"notes\": \"Purinergic signaling modulates astrocyte polarization and tumor growth\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"GFAP\",\n        \"ALDH1L1\",\n        \"CD44\",\n        \"ATP1A2\"\n      ]\n    },\n    {\n      \"program_name\": \"Gap junction communication and chemoresistance\",\n      \"description\": \"Connexin 43 (GJA1) forms gap junctions enabling intercellular communication but also confers chemoresistance to temozolomide (TMZ) and other chemotherapeutic agents. Cx43 is highly expressed in a subpopulation of GBM; Cx43 mRNA strongly correlates with poor prognosis and chemoresistance. Cx43 activates PI3K (specifically PIK3CB/p110β) signaling independent of its channel function (non-channel function). CD38 ectoenzyme activity may modulate adenosine levels affecting gap junction function. Combining Cx43 inhibition (αCT1 peptide) with PI3K inhibitors (TGX-221, GSK2636771) sensitizes GBM to TMZ.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"gap junction protein function and intercellular communication\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"GJA1 (Cx43) forms gap junctions; mRNA levels strongly correlate with poor prognosis and chemoresistance\"\n            }\n          ],\n          \"genes\": [\n            \"GJA1\"\n          ]\n        },\n        {\n          \"name\": \"non-channel Cx43-mediated PI3K activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"Cx43 activates PI3K signaling independent of channel function; specifically requires PIK3CB/p110β\"\n            }\n          ],\n          \"genes\": [\n            \"GJA1\"\n          ]\n        },\n        {\n          \"name\": \"chemoresistance signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"High Cx43 in MGMT-deficient GBM cells confers TMZ resistance; αCT1 and p110β inhibitors overcome resistance\"\n            }\n          ],\n          \"genes\": [\n            \"GJA1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"plasma membrane gap junction protein complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"Connexin proteins comprise gap junctions; mediate protein-protein interactions and communication\"\n            }\n          ],\n          \"genes\": [\n            \"GJA1\"\n          ]\n        },\n        {\n          \"name\": \"PI3K signaling complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"Cx43 interacts with PI3K catalytic subunit p110β; activation occurs in Cx43/p110β precipitates\"\n            }\n          ],\n          \"genes\": [\n            \"GJA1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced intercellular communication enabling collective tumor behavior\",\n        \"Activation of PI3K/AKT survival signaling independent of chemotherapy\",\n        \"Increased resistance to temozolomide and other chemotherapeutic agents\",\n        \"Poor treatment response and shortened progression-free survival\",\n        \"Maintenance of tumor cell viability despite DNA-damaging therapies\"\n      ],\n      \"evidence_summary\": \"Connexin 43 (GJA1) emerges as a critical determinant of GBM chemoresistance, particularly to temozolomide. Cx43 is highly expressed in a subpopulation of GBM, and its mRNA levels show strong correlation with poor prognosis and treatment resistance. Mechanistically, Cx43 confers chemoresistance through non-channel functions, specifically by activating PI3K (particularly the p110β catalytic isoform). This activation is MGMT-independent, explaining why some MGMT-deficient tumors still show chemoresistance. Combining Cx43 inhibition (using the αCT1 peptide, which has been clinically tested) with selective PIK3CB/p110β inhibitors (TGX-221, GSK2636771) synergistically overcomes TMZ resistance both in vitro and in vivo. This represents a rational combination therapy strategy targeting a fundamental resistance mechanism.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"Connexin 43 confers chemoresistance through PI3K/p110β activation\"\n        },\n        {\n          \"source_id\": \"30\",\n          \"notes\": \"Connexin 43 drives GBM cancer stem cell phenotypes\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"GJA1\",\n        \"CD38\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PIK3CB\",\n          \"AKT1\",\n          \"PTEN\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"27\",\n            \"notes\": \"PI3K/AKT/mTOR cascade activated downstream of Cx43; PTEN loss promotes pathway activation\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Pericyte recruitment and vascular stability\",\n      \"description\": \"Pericytes (mural cells) are recruited to glioma vasculature through PDGF-B/PDGFR-β signaling. Pericytes play paradoxical roles: structurally supporting vessel formation but also promoting treatment resistance. NG2 (a pericyte marker not in input list) isoforms in proliferative perivascular pericytes promote early angiogenesis and vasculogenic mimicry. PDGFRB signaling activates PI3K, promoting pericyte recruitment to hypoxic tumor regions. Two pericyte subtypes exist: Type-1 (non-contributing to new vessel formation; can differentiate to tumor-associated fibroblasts) and Type-2 (pro-angiogenic). Hypoxia induces HIF-1α-mediated PDGF-β expression in endothelial cells, recruiting pericytes. Anti-VEGF therapies lead to increased pericyte vessel coverage, promoting vascular stabilization and therapy resistance.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"PDGF-B/PDGFR-β mediated pericyte recruitment\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"Hypoxia induces HIF-1α-mediated PDGF-β expression in endothelial cells; promotes PDGFR-β signaling in pericytes and migration\"\n            }\n          ],\n          \"genes\": [\n            \"PDGFRB\"\n          ]\n        },\n        {\n          \"name\": \"pericyte-endothelial cell paracrine signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"Pericytes produce TGF-β, VEGF, HGF; create paracrine loop with endothelial cells via Ang-1/Tie-2 signaling\"\n            }\n          ],\n          \"genes\": [\n            \"PDGFRB\"\n          ]\n        },\n        {\n          \"name\": \"resistance to anti-VEGF therapy\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"Anti-VEGF therapy initially reduces endothelial cell density but leads to increased pericyte vessel coverage and vascular stabilization\"\n            }\n          ],\n          \"genes\": [\n            \"PDGFRB\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"perivascular pericyte niche\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"Pericytes recruited to hypoxic regions; establish critical interactions with endothelial cells modulating vascular stability\"\n            }\n          ],\n          \"genes\": [\n            \"PDGFRB\"\n          ]\n        },\n        {\n          \"name\": \"PDGFR-β signaling platform\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"PDGFR-β mediates PI3K activation and pericyte migration toward newly formed immature microvessels\"\n            }\n          ],\n          \"genes\": [\n            \"PDGFRB\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced tumor vascular network formation and stabilization\",\n        \"Recruitment of pericytes to hypoxic tumor regions\",\n        \"Support for glioma stem cell maintenance in perivascular niche\",\n        \"Increased resistance to anti-angiogenic therapies (bevacizumab)\",\n        \"Promotion of vascular invasion and infiltration\",\n        \"Development of abnormal vascular patterns with atypical pericyte coverage\"\n      ],\n      \"evidence_summary\": \"Pericytes play a multifaceted role in gBM vascular biology and treatment resistance. PDGF-B/PDGFR-β signaling is the primary mechanism recruiting pericytes to tumor vasculature, particularly in hypoxic regions. Hypoxia-inducible factor-1α (HIF-1α) upregulates PDGF-β expression in endothelial cells, creating a hypoxia-driven recruitment loop. Pericytes produce pro-angiogenic factors (VEGF, TGF-β, hepatocyte growth factor) and maintain vascular integrity through Ang-1/Tie-2 signaling. Importantly, anti-VEGF therapies paradoxically increase pericyte vessel coverage, promoting vascular stabilization and therapy resistance. Two functionally distinct pericyte subtypes have been characterized: Type-1 pericytes can differentiate to tumor-associated fibroblasts and contribute to ECM; Type-2 pericytes directly induce angiogenesis and are recruited specifically to sites of active tumor neovascularization.\",\n      \"significance_score\": 0.76,\n      \"citations\": [\n        {\n          \"source_id\": \"14\",\n          \"notes\": \"Pericytes in glioblastoma: hidden regulators of tumor vasculature and treatment resistance\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PDGFRB\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PDGFB\",\n          \"NG2\",\n          \"VEGFR2\",\n          \"VEGFA\",\n          \"TGF-BETA1\",\n          \"HIF1A\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"14\",\n            \"notes\": \"PDGF-B secreted by endothelial cells; NG2 expressed by proliferative pericytes; VEGF-A and TGF-β produced by pericytes\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Immune cell infiltration and M2 macrophage polarization\",\n      \"description\": \"Multiple genes in this list promote M1-to-M2 macrophage polarization and creation of an immunosuppressive tumor microenvironment. CHI3L2 (YKL40) is secreted by tumor cells and immune cells (particularly macrophages), promoting M2-like activation. COLEC12 (C-type lectin) functions as a scavenger receptor upregulated on M2 macrophages. ZFP36L2 correlates with immune infiltration and is positively associated with M2 macrophage markers. Complement components (C3, C3a) promote M2 polarization through C3aR signaling on macrophages. NMB (neuromedin B) expression correlates with immune infiltration and improved GBM survival. OSMR and other cytokine receptors on myeloid cells support immune cell recruitment and polarization.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"M2 macrophage polarization and activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"34\",\n              \"notes\": \"C3a induces M2 polarization of cultured microglia and macrophages in C3aR-dependent fashion\"\n            },\n            {\n              \"source_id\": \"59\",\n              \"notes\": \"Scavenger immunosuppressive program in myeloid cells includes MRC1, MSR1, CD163, LYVE1, COLEC12\"\n            }\n          ],\n          \"genes\": [\n            \"C3\",\n            \"CHI3L2\",\n            \"COLEC12\",\n            \"ZFP36L2\"\n          ]\n        },\n        {\n          \"name\": \"immune infiltration and lymphocyte recruitment\",\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"ZFP36L2 high expression significantly positively correlated with immune infiltration and immune checkpoint PD-L1\"\n            },\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"NMB expression correlated with tumor-infiltrating lymphocytes; associated with better survival\"\n            }\n          ],\n          \"genes\": [\n            \"ZFP36L2\",\n            \"NMB\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"macrophage scavenger receptors and pattern recognition\",\n          \"citations\": [\n            {\n              \"source_id\": \"59\",\n              \"notes\": \"COLEC12 functions as pattern-recognition scavenger receptor; expressed on M2 macrophages\"\n            }\n          ],\n          \"genes\": [\n            \"COLEC12\",\n            \"CHI3L2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Recruitment and infiltration of macrophages/microglia into tumor microenvironment\",\n        \"Shift of macrophage phenotype from pro-inflammatory (M1) to immunosuppressive (M2) state\",\n        \"Increased expression of immunosuppressive cytokines (IL-10, TGF-β)\",\n        \"Enhanced T cell exhaustion and impaired anti-tumor immunity\",\n        \"Support for tumor angiogenesis and invasive phenotype\",\n        \"Creation of permissive microenvironment for GSC maintenance\"\n      ],\n      \"evidence_summary\": \"Immune cell polarization toward M2 (immunosuppressive) phenotypes is a hallmark of GBM progression. CHI3L2 (YKL40) is secreted by tumor and immune cells and promotes M2 macrophage activation while inducing CD8+ T cell apoptosis, explaining the dual pro-tumor effects. COLEC12 functions as a scavenger receptor on M2 macrophages, recognizing patterns that promote immunosuppression. Complement C3a potently drives M3 macrophage polarization through C3aR signaling. ZFP36L2 high expression correlates with immune infiltration and poor prognosis, with enrichment of M1 macrophage markers in non-responders. Interestingly, NMB shows the opposite pattern—high NMB expression predicts better survival and is associated with enhanced immune infiltration, suggesting heterogeneity in immune responses. This program illustrates how tumors co-opt immune cells to create an immunosuppressive microenvironment.\",\n      \"significance_score\": 0.83,\n      \"citations\": [\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"CHI3L2 is prognostic biomarker correlated with immune infiltrates in glioma\"\n        },\n        {\n          \"source_id\": \"20\",\n          \"notes\": \"ZFP36L2 expression positively correlated with immune infiltration and poor prognosis\"\n        },\n        {\n          \"source_id\": \"34\",\n          \"notes\": \"Hypoxia-induced C3 promotes M2 macrophage polarization\"\n        },\n        {\n          \"source_id\": \"51\",\n          \"notes\": \"NMB expression associated with immune infiltration and improved GBM survival\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CHI3L2\",\n        \"COLEC12\",\n        \"ZFP36L2\",\n        \"C3\",\n        \"NMB\"\n      ]\n    },\n    {\n      \"program_name\": \"Metabolic reprogramming and hypoxia adaptation\",\n      \"description\": \"Gliomas undergo profound metabolic rewiring to survive hypoxic microenvironments and aggressive selection pressures. Hypoxia-inducible factor-1α (HIF-1α) is a master regulator activating genes for glycolysis, angiogenesis, and stemness. PFKFB3 is the most highly expressed glycolytic enzyme and undergoes post-translational modifications (O-GlcNAcylation, phosphorylation) in response to hypoxia. HAS2 and HAS3 (hyaluronic acid synthases) are upregulated under hypoxia and glycolytic conditions. Endothelin signaling (EDNRA/EDNRB) is hypoxia-responsive and promotes both metabolic adaptation and GSC stemness. This program bridges metabolic, signaling, and stemness programs, reflecting the integrated nature of GBM adaptation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"hypoxia-induced gene expression and HIF-1α signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"Hypoxia upregulates EDN1, EDNRA, EDNRB expression through HIF-1α and ERN1-dependent mechanisms\"\n            }\n          ],\n          \"genes\": [\n            \"EDNRA\",\n            \"EDNRB\"\n          ]\n        },\n        {\n          \"name\": \"hypoxia-dependent glycolytic enzyme expression\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Hypoxia induces PFKFB3 expression and O-GlcNAcylation; maintains cancer cell division under hypoxic stress\"\n            }\n          ],\n          \"genes\": [\n            \"PFKFB3\"\n          ]\n        },\n        {\n          \"name\": \"hypoxia-responsive ECM synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"HAS2 (hyaluronic acid synthase) highly expressed in GBM; expression drives tumor progression\"\n            }\n          ],\n          \"genes\": [\n            \"HAS2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"post-translational modification sites in metabolic enzymes\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"PFKFB3 undergoes O-GlcNAcylation at Ser172 by OGT; alternatively phosphorylated by ERK; mutually exclusive modifications regulate nuclear translocation\"\n            }\n          ],\n          \"genes\": [\n            \"PFKFB3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Coordinated upregulation of glycolytic pathway under hypoxia\",\n        \"Maintenance of tumor cell viability in oxygen-deprived regions\",\n        \"Enhanced stemness signaling through hypoxia-responsive pathways\",\n        \"Increased ECM synthesis supporting tumor architecture\",\n        \"Metabolic adaptation supporting rapid proliferation and invasion\",\n        \"Coupling of metabolic and stemness programs through HIF-1α and endothelin signaling\"\n      ],\n      \"evidence_summary\": \"Metabolic reprogramming and hypoxia adaptation represent integrated processes in GBM driven by HIF-1α and complementary signaling pathways. PFKFB3 emerges as a central hub, with its expression and activity controlled by multiple post-translational modifications in response to hypoxia. O-GlcNAcylation of PFKFB3 by OGT (triggered by glucose availability during glycolysis) promotes nuclear translocation and cell cycle progression, while ERK phosphorylation causes cytoplasmic retention—these represent mutually exclusive regulatory mechanisms. Endothelin signaling (EDNRA/EDNRB) represents a hypoxia-responsive pathway coupling metabolic adaptation with GSC stemness maintenance. HAS2 upregulation under hypoxia drives excessive hyaluronic acid synthesis, creating a denser, more resistant ECM. This program illustrates how GBM coordinates multiple survival mechanisms in response to hostile microenvironmental conditions.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"37\",\n          \"notes\": \"Hypoxia-induced PFKFB3 O-GlcNAcylation and metabolic reprogramming\"\n        },\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"HAS2 facilitates glioma malignancy under various metabolic conditions\"\n        },\n        {\n          \"source_id\": \"18\",\n          \"notes\": \"Hypoxia-dependent endothelin system expression\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PFKFB3\",\n        \"HAS2\",\n        \"EDNRA\",\n        \"EDNRB\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"HIF1A\",\n          \"EGFR\",\n          \"PTEN\",\n          \"TP53\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"37\",\n            \"notes\": \"HIF-1α is master regulator of hypoxic adaptation; PFKFB3 induction is HIF-1α-dependent\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Pathway databases (KEGG, Reactome)\",\n      \"Co-citation analysis from glioblastoma literature\",\n      \"Protein-protein interaction networks\",\n      \"Functional roles in glioma cell migration, stemness, metabolism, immune evasion\",\n      \"Spatial transcriptomics data showing tumor microenvironment organization\",\n      \"Single-cell transcriptomics revealing cell type-specific expression programs\"\n    ],\n    \"notes\": \"Gene programs were derived by identifying functionally coherent clusters from the input gene list. Programs prioritize genes with multiple literature citations in the GBM context and those showing coordinated regulation. Programs avoid grouping loosely related processes and instead represent tightly integrated biological programs. Significance scores reflect both the number of supporting genes from the input list and the strength of literature evidence. Several well-established GBM programs could not be fully characterized due to missing genes (e.g., receptor tyrosine kinase signaling lacks key components like EGFR, MET, IGF1R despite EGF being present).\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n## Citations\n\n1. https://www.oncotarget.com/article/16017/text/\n2. https://pmc.ncbi.nlm.nih.gov/articles/PMC9508470/\n3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3408254/\n4. https://pmc.ncbi.nlm.nih.gov/articles/PMC1993862/\n5. https://pmc.ncbi.nlm.nih.gov/articles/PMC12539703/\n6. https://pmc.ncbi.nlm.nih.gov/articles/PMC7651462/\n7. https://cdnsciencepub.com/doi/10.1139/o96-090\n8. https://pmc.ncbi.nlm.nih.gov/articles/PMC12010881/\n9. https://pmc.ncbi.nlm.nih.gov/articles/PMC11335651/\n10. https://pubmed.ncbi.nlm.nih.gov/34781885/\n11. https://pubmed.ncbi.nlm.nih.gov/37587889/\n12. https://www.nature.com/articles/s41598-023-49801-y\n13. https://pmc.ncbi.nlm.nih.gov/articles/PMC11309948/\n14. https://pmc.ncbi.nlm.nih.gov/articles/PMC11718950/\n15. https://pmc.ncbi.nlm.nih.gov/articles/PMC3245317/\n16. https://www.nature.com/articles/s41419-021-03747-z\n17. https://www.nature.com/articles/s41467-024-55487-1\n18. https://pubmed.ncbi.nlm.nih.gov/31734650/\n19. https://pubmed.ncbi.nlm.nih.gov/24413082/\n20. https://pmc.ncbi.nlm.nih.gov/articles/PMC9334557/\n21. https://pmc.ncbi.nlm.nih.gov/articles/PMC3909648/\n22. https://pmc.ncbi.nlm.nih.gov/articles/PMC2931346/\n23. https://www.nature.com/articles/s41467-025-58993-y\n24. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2022.916055/full\n25. https://www.nature.com/articles/cddis2013279\n26. https://pmc.ncbi.nlm.nih.gov/articles/PMC5409228/\n27. https://www.nature.com/articles/s41389-022-00378-7\n28. https://pmc.ncbi.nlm.nih.gov/articles/PMC3362965/\n29. https://www.frontiersin.org/journals/neuroanatomy/articles/10.3389/fnana.2021.591726/full\n30. https://pubmed.ncbi.nlm.nih.gov/40946315/\n31. https://pmc.ncbi.nlm.nih.gov/articles/PMC6134703/\n32. https://pmc.ncbi.nlm.nih.gov/articles/PMC1861510/\n33. https://www.nature.com/articles/s41698-025-00956-z\n34. https://insight.jci.org/articles/view/179854\n35. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.931273/full\n36. https://www.ncbi.nlm.nih.gov/gene/63827\n37. https://www.nature.com/articles/s41389-020-0208-1\n38. https://pmc.ncbi.nlm.nih.gov/articles/PMC8766410/\n39. https://pmc.ncbi.nlm.nih.gov/articles/PMC2586684/\n40. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1522392/full\n41. https://pubmed.ncbi.nlm.nih.gov/9298845/\n42. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.943300/full\n43. https://www.embopress.org/doi/10.15252/embr.202051182\n44. https://pmc.ncbi.nlm.nih.gov/articles/PMC4569307/\n45. https://pmc.ncbi.nlm.nih.gov/articles/PMC8084183/\n46. https://v22.proteinatlas.org/ENSG00000135063-FAM189A2\n47. https://pmc.ncbi.nlm.nih.gov/articles/PMC8740521/\n48. https://pmc.ncbi.nlm.nih.gov/articles/PMC10976000/\n49. https://pmc.ncbi.nlm.nih.gov/articles/PMC5494611/\n50. https://pmc.ncbi.nlm.nih.gov/articles/PMC2778682/\n51. https://article.imrpress.com/journal/FBL/28/3/10.31083/j.fbl2803054/a47bb4b76a1c75c038a24fbc148290c6.pdf\n52. https://pmc.ncbi.nlm.nih.gov/articles/PMC5860944/\n53. https://aacrjournals.org/cancerres/article/79/16/4026/638334/Identification-of-Novel-RAS-Signaling-Therapeutic\n54. https://pubmed.ncbi.nlm.nih.gov/37005748/\n55. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.657472/full\n56. https://pmc.ncbi.nlm.nih.gov/articles/PMC10734338/\n57. https://pmc.ncbi.nlm.nih.gov/articles/PMC12147667/\n58. https://pubmed.ncbi.nlm.nih.gov/12502731/\n59. https://www.nature.com/articles/s41586-025-08633-8\n60. https://www.nature.com/articles/s41598-025-12926-3",
    "citations": [],
    "duration_seconds": 171.69
  }
}